40.48

5.24% -2.24

After Hours: 40.55 0.07 +0.17%

Akero Therapeutics Inc (AKRO)

Overview News Price History Option Chain Financials Why AKRO Down? Discussions Forecast

Akero Therapeutics Inc stock is traded at $40.48, with a volume of 1.39M. It is down -5.24% in the last 24 hours and down -17.59% over the past month. Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

Previous Close:

$42.72

Open:

$40.9

24h Volume:

1.39M

Relative Volume:

1.13

Market Cap:

$3.23B

Revenue:

Net Income/Loss:

$-237.22M

P/E Ratio:

-10.71

EPS:

-3.78

Net Cash Flow:

$-212.64M

1W Performance:

-10.20%

1M Performance:

-17.59%

6M Performance:

+41.09%

1Y Performance:

+60.25%

1-Day Range:

$39.18

$41.12

1-Week Range:

$39.18

$45.38

52-Week Range:

$17.86

$58.40

Akero Therapeutics Inc Stock (AKRO) Company Profile

Name

Akero Therapeutics Inc

Sector

Healthcare (1164)

Industry

Biotechnology (681)

Phone

650-487-6488

Address

601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA

Employee

Twitter

@akerotx

Next Earnings Date

2024-11-11

Latest SEC Filings

AKRO's Discussions on Twitter

Compare AKRO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AKRO Akero Therapeutics Inc	40.48	3.23B	0	-237.22M	-212.64M	-3.78
VRTX Vertex Pharmaceuticals Inc	484.82	131.41B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	634.23	72.26B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	591.87	36.10B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	270.02	35.03B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	272.17	28.24B	3.81B	-644.79M	-669.77M	-6.24

Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-30-25	Upgrade	BofA Securities	Neutral → Buy
Jan-27-25	Reiterated	H.C. Wainwright	Buy
Nov-18-24	Initiated	Citigroup	Buy
Apr-22-24	Resumed	BofA Securities	Neutral
Sep-19-23	Initiated	Cantor Fitzgerald	Overweight
Aug-28-23	Initiated	UBS	Buy
Jan-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Sep-14-22	Upgrade	Evercore ISI	In-line → Outperform
Oct-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-10-21	Initiated	BofA Securities	Buy
Feb-26-21	Initiated	Guggenheim	Buy
Sep-10-20	Initiated	Morgan Stanley	Overweight
Jul-20-20	Reiterated	H.C. Wainwright	Buy
Jul-07-20	Initiated	Chardan Capital Markets	Buy
Jul-01-20	Reiterated	H.C. Wainwright	Buy
Mar-02-20	Initiated	H.C. Wainwright	Buy
Feb-10-20	Initiated	Canaccord Genuity	Buy
Jul-15-19	Initiated	Evercore ISI	Outperform
Jul-15-19	Initiated	JP Morgan	Overweight
Jul-15-19	Initiated	Jefferies	Buy
Jul-15-19	Initiated	ROTH Capital	Buy

View All

Akero Therapeutics Inc Stock (AKRO) Latest News

06:40 AM

Possible Bearish Signals With Akero Therapeutics Insiders Disposing Stock - simplywall.st

06:40 AM

Mar 30, 2025

Akero Therapeutics (NASDAQ:AKRO) Stock Price Down 6.3%Time to Sell? - MarketBeat

Mar 30, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Shareholders to Learn More About the Investigation - markets.businessinsider.com

Mar 30, 2025

Proficio Capital Partners LLC Takes Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat

Mar 30, 2025

Mar 29, 2025

Akero Therapeutics (NASDAQ:AKRO) Shares Gap Up Following Insider Buying Activity - MarketBeat

Mar 29, 2025

How To Trade (AKRO) - news.stocktradersdaily.com

Mar 29, 2025

Mar 28, 2025

G. Walmsley Graham Acquires 50,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock - MarketBeat

Mar 28, 2025